All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Kjeld SchmiegelowSteering Committee Member

Kjeld Schmiegelow is a clinical professor at the Department of Clinical Medicine, University of Copenhagen, DK, and Head of Pediatric Oncology and Consultant of Pediatric and Adolescent Medicine at the Juliane Marie Centre, Rigshospitalet. He is currently founder and chair of the International Ponte di Legno Toxicity Working Group, a member of the European I-BFM ALL Host Genetic Variation Working Group, and chair of the Host Genome Variant Leukemia/Lymphoma Working Group of the EU COST LEGEND network. His main research interests include the etiology of childhood cancer; leukemia biology, including CNS tumors; the pharmacology of anticancer agents, including the genetics, kinetics, dynamics, and toxicities associated with these agents; and the late somatic and psychosocial effects of childhood cancer and rehabilitation.

|